F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Savira pharmaceuticals GmbH was founded in July 2009 by the European Molecular Biology Laboratory (EMBL), onepharm Research and Development GmbH, private investors, and management. Led by CEO Oliver Szolar and CSO Helmut Buschmann, a seasoned management team combines scientific, technological, and business experience in the pharmaceutical industry. Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-influenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from influenza, and add to the arsenal of antivirals thus improving influenza pandemic preparedness.

Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.

3M Innovative Properties Co. acquires and manages intellectual property right. It engages in the acquisition and ownership of the intellectual property rights to the products designed and manufactured by its parent company 3M Corporation. The company was founded on May 10, 1999 and is headquartered in Roseville, MN.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Medikine, Inc. is an American company located in Menlo Park, CA, that operates as preclinical-stage biopharmaceutical company. Ronald W. Barrett has been the CEO since 2016.\nThe company says this about itself: Medikine is a biopharmaceutical company with a mission to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular ��PEPTIKINES��- peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. These PEPTIKINES are engineered for low immunogenicity and are readily amenable to the incorporation of targeting and other pharmacological features. Medikine��s lead candidate, MDK-703, currently in a Phase 1 clinical trial in healthy volunteers, is an IL-7 PEPTIKINE fused to an immunoglobulin Fc-domain. MDK-703 emulates the beneficial properties of IL-7, a cytokine critical for maintenance of T cell responses.

Shandong Dyne Marine Bio-Pharmaceutical Co., Ltd., established on 1994-10-27, Business scope includes general items:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Advertising Design,acting;advertising(non-broadcasting station,television station,Newspaper Publishing Unit);advertisement making;Information Consulting Service(Not including licensing information consulting services);Cosmetics Wholesale;Cosmetics Retail(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Drug Wholesale;Drug retail;food production;food business(Selling prepackaged food);Import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Sichuan Kelun Botai Biomedical Co., Ltd., established on 2016-11-22, Business scope includes biopharmaceuticals,Chemical Raw Materials,Research and development of chemical preparations,production and sales;Import and export,Technology Import and Export;Technical extension services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines. It offers drugs in the form of tablets, capsules, pills, granules, injections, and oral liquids. Its products are used for treatment of cardiovascular and cerebrovascular diseases including stroke, arrhythmia, insufficiency of blood supply, and ischemic infarction. It also provides medicines for diabetes, urinary and digestive, respiratory, and gynecological diseases. The company was founded by Bu Chang Zhao on May 10, 2001 and is headquartered in Heze, China.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA.

RocketVax AG is a company headquartered in Basel, Switzerland, that engages in development of vaccines. It was founded in 2020 by Vladimir Cmiljanovic, who has been the CEO since that date.\nThe company says this about itself: RocketVax was established through a collaboration between Swiss Rockets AG, a Swiss-based incubator and accelerator for startups focusing on innovative therapies, and a team of accomplished scientists from esteemed institutions, including the Universities of Basel and Zurich, ETH Zurich, University Hospital Basel, Swiss Tropical and Public Health Institute in Basel, and Gigabases Switzerland AG, a spinoff of ETH Zurich. Currently, RocketVax's primary focus is on developing a group of vaccines to address the SARS-CoV-2 virus. These vaccines undergo rigorous preclinical testing to ensure their efficacy and safety before progressing to human clinical trials. Using proprietary molecular biology technologies, RocketVax is dedicated to developing novel vaccines for various infectious diseases, including COVID-19, cancer, and auto-immune disorders. The team at RocketVax has three COVID-19 vaccine candidates in their pipeline, including two live-attenuated SARS-CoV-2 virus vaccines and the replication-incompetent SARS-CoV-2 virus vaccine.

CuraGen Corporation is a biopharmaceutical development company that develops novel therapeutics for the treatment of cancer in the United States and Europe. Its therapeutics is based on novel targets from the human genome that play a role in proven mechanisms underlying disease. The Company's strategy continues to be focused on advancing its pipeline of pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes, promising therapeutics through clinical and preclinical development. CuraGen Corporation was founded in 1991 and is headquartered in Branford, Connecticut. As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc.

Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Their clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer, and AML. They are also engaged in the preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Sunshine Lake Pharma Co. Ltd., a subsidiary of Shenzhen Dongyangguang Industry Co., Ltd., is a Chinese company. The firm manufactures and supplies pharmaceutical ingredients and drugs. Wen Jia Li has been the CEO since 2021. On December 23, 2022 Shenzhen Dongyangguang Industry Co., Ltd. acquired Sunshine Lake Pharma Co. Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd. for $330.99 million.